drugset

drugset / Trial / NCT04681131

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

NCT04681131 ↗

Phase 2 Completed 85 enrolled BioAtla, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Timeline

Start: 2021-03-17
Primary completion: 2025-07-09
Completion: 2025-07-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mecbotamab vedotin	Unknown	—	—

Indications